Integrated Filing — IndAS



General information about company

Scrip Code 532612
NSE Symbol INDOCO
MSEI Symbol NOTLISTED
ISIN INE873D01024
Name of company INDOCO REMEDIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 07-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 27-04-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment PHARMACEUTICALS
Start date and time of board meeting 07-05-2026   11:05:00
End date and time of board meeting 07-05-2026   12:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 25-03-2025
Indicate Company website link for updated RPT policy of the Company https://www.indoco.com/policies/Policy_on_Materiality_of_Related_Party_Transactions_March2025.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company does not have any debt securities and there are no defaults on loan taken by the Company for the quarter and year ended 31st March, 2026. Hence the said disclosure is not applicable to the Company.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 44,913.00 1,68,607.00
Other income 1,035.00 2,964.00
Total income 45,948.00 1,71,571.00
2 Expenses
(a) Cost of materials consumed 9,825.00 35,323.00
(b) Purchases of stock-in-trade 2,908.00 14,012.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 1,058.00 720.00
(d) Employee benefit expense 10,098.00 39,363.00
(e) Finance costs 2,273.00 8,850.00
(f) Depreciation, depletion and amortisation expense 2,671.00 10,690.00
(f) Other Expenses
1 Research & Development Expense 1,776.00 7,954.00
2 Other Expenses 12,945.00 55,520.00
Total other expenses 14,721.00 63,474.00
Total expenses 43,554.00 1,72,432.00
3 Total profit before exceptional items and tax 2,394.00 (861.00)
4 Exceptional items 368.00 (286.00)
5 Total profit before tax 2,762.00 (1,147.00)
6 Tax expense
7 Current tax 292.00 292.00
8 Deferred tax (265.00) (873.00)
9 Total tax expenses 27.00 (581.00)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 2,735.00 (566.00)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 2,735.00 (566.00)
17 Other comprehensive income net of taxes 50.00 133.00
18 Total Comprehensive Income for the period 2,785.00 (433.00)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,846.00 1,846.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 1,08,073.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.96 -0.61
Diluted earnings (loss) per share from continuing operations 2.96 -0.61
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.96 -0.61
Diluted earnings (loss) per share from continuing and discontinued operations 2.96 -0.61
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The audited Standalone Results for the Quarter and Year ended 31st March, 2026 have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 07th May, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these audited Standalone Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The Board of Directors have proposed, subject to the approval of shareholders in the ensuing Annual General Meeting a Dividend of 10% i.e. 0.20 per equity share on face value of Rs. 2/-each to its equity shareholder's for the year 2025-2026. 4.In Nomination and Remuneration Committee meeting held on 03rd February 2026, the Company has allotted 55,700 number of equity shares to Indoco Employees Welfare Trust under Indoco Remedies Limited Employee Stock Option Plan-2022. 5.The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 6. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: (Rs. in lakhs) -------------------------------------------------------------------------------------------------------------------------------- Net Sales Qtr ended Qtr ended Qtr ended Year ended Year ended & Income 31-03-2026 31-12-2025 31-03-2025 31-03-2026 31-03-2025 from Operations (Audited) (Unaudited) (Audited) (Audited) (Audited) ---------------------------------------------------------------------------------------------------------------------------------- India 19,363 23,060 21,639 89,413 91,598 Outside India 23,543 15,897 12,468 73,941 57,880 --------------------------------------------------------------------------------------------------------------------------------- Total : 42,906 38,957 34,107 1,63,354 1,49,478 ================================================================= 7. Figures for the quarter ended 31.3.2026 and 31.3.2025 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2025 (limited reviewed) and 31.12.2024 (limited reviewed). 8. (*) Exceptional items during the year includes : (a) Consideration received Rs. 346 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, (b) Loss amounting to Rs. 213 lakhs on sale and leaseback of its Non current Assets, and, (c) Impact of past period employee benefit liability amounting to Rs. 419 lakhs due to implementation of the New Labour Codes. 9. Effective 21 November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 419 lakhs primarily arising due to change in definition of wages for employees and contract labours. Considering the materiality and nonrecurring nature of this impact, the Company has presented such incremental impact under 'Exceptional Item in the standalone financial results for the year ended 31st March, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 70,346.00
Capital work-in-progress 2,349.00
Investment property
Goodwill 0.00
Other intangible assets 14,799.00
Intangible assets under development 6,172.00
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 15,975.00
Trade receivables, non-current
Loans, non-current 5,056.00
Other non-current financial assets
1 Other Financial Assets 786.00
Total of other non-current financial assets 786.00
Total non-current financial assets 21,817.00
Deferred tax assets (net)
Other non-current assets
1 Other Non-Current Assets 9,655.00
Total of other non-current assets 9,655.00
Total non-current assets 1,25,138.00
2 Current assets
Inventories 32,183.00
Current financial asset
Current investments 0.00
Trade receivables, current 54,120.00
Cash and cash equivalents 1,294.00
Bank balance other than cash and cash equivalents 706.00
Loans, current 456.00
Other current financial assets
Total of other current financial assets 3,559.00
Total current financial assets 60,135.00
Current tax assets (net) 2,136.00
Other current assets
1 Other Current Assets 14,577.00
2 Assets Classified as held for Sale 2,341.00
Total of other current assets 16,918.00
Total current assets 1,11,372.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 2,36,510.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,846.00
Other equity 1,08,073.00
Total equity attributable to owners of parent 1,09,919.00
Non controlling interest
Total equity 1,09,919.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 30,161.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 4,234.00
2 Other Financial Liabilities 275.00
Total of other non-current financial liabilities 4,509.00
Total non-current financial liabilities 34,670.00
Provisions, non-current 3,468.00
Deferred tax liabilities (net) 157.00
Deferred government grants, Non-current
Other non-current liabilities
1 Other Non-Current Liabilities 749.00
Total of other non-current liabilities 749.00
Total non-current liabilities 39,044.00
Current liabilities
Current financial liabilities
Borrowings, current 40,399.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 8,184.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 17,871.00
Total Trade payable 26,055.00
Other current financial liabilities
1 Lease Liabilities 1,156.00
2 Other Financial Liabilities 9,629.00
Total of other current financial liabilities 10,785.00
Total current financial liabilities 77,239.00
Other current liabilities 5,667.00
1 Other Current Liabilities 5,667.00
Total of other current liabilities 5,667.00
Provisions, current 4,641.00
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 87,547.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 1,26,591.00
Total equity and liabilites 2,36,510.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit and loss 403.00 178.00
Total Amount of items that will not be reclassified to profit and loss 403.00 178.00
2 Income tax relating to items that will not be reclassified to profit or loss 102.00 45.00
3 Amount of items that will be reclassified to profit and loss
1 Items that may be reclassified to profit or loss (335.00) 0.00
Total Amount of items that will be reclassified to profit and loss (335.00) 0.00
4 Income tax relating to items that will be reclassified to profit or loss (84.00) 0.00
5 Total Other comprehensive income 50.00 133.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (1,147.00)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 8,850.00
Adjustments for decrease (increase) in inventories 4,103.00
Adjustments for decrease (increase) in trade receivables, current (17,107.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (981.00)
Adjustments for decrease (increase) in other non-current assets (1,553.00)
Adjustments for other financial assets, non-current (152.00)
Adjustments for other financial assets, current (444.00)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 11,319.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 3,443.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 10,690.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 135.00
Adjustments for provisions, non-current 157.00
Adjustments for other financial liabilities, current 2,396.00
Adjustments for other financial liabilities, non-current 4,776.00
Adjustments for unrealised foreign exchange losses gains (924.00)
Adjustments for dividend income 0.00
Adjustments for interest income 1,768.00
Adjustments for share-based payments 60.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 1,315.00
Other adjustments for non-cash items 60.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 24,375.00
Net cash flows from (used in) operations 23,228.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 593.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 22,635.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 10,779.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 4,426.00
Purchase of property, plant and equipment 12,535.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 680.00
Cash receipts from repayment of advances and loans made to other parties 9,270.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 1,769.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (209.00)
Net cash flows from (used in) investing activities (8,738.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 130.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 5,300.00
Repayments of borrowings 8,538.00
Payments of lease liabilities 1,096.00
Dividends paid 191.00
Interest paid 8,914.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (13,309.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 588.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 588.00
Cash and cash equivalents cash flow statement at beginning of period 706.00
Cash and cash equivalents cash flow statement at end of period 1,294.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s. Gokhale & Sathe Yes 28-02-2027


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 INDOCO REMEDIES LIMITED Suresh Govind Kare- HUF Promoter Any other transaction Payment of Godown Rent 7.50 NA 1.50 0.00 0.00
2 INDOCO REMEDIES LIMITED A K Services & Agency Private Limited (Formerly known as A. K. Services) Mrs. Aditi Panandikar Managing Director of the Company is the Director of A K Services & Agency Private Limited Purchase of goods or services 300.00 NA 64.38 7.97 36.37 Textual Information(1)
3 INDOCO REMEDIES LIMITED A K Services & Agency Private Limited (Formerly known as A. K. Services) Mrs. Aditi Panandikar Managing Director of the Company is the Director of A K Services & Agency Private Limited Purchase of goods or services 75.00 NA 10.80 1.80 4.18 Textual Information(2)
4 INDOCO REMEDIES LIMITED A K Services & Agency Private Limited (Formerly known as A. K. Services) Mrs. Aditi Panandikar Managing Director of the Company is the Director of A K Services & Agency Private Limited Interest paid 2.00 NA 0.37 0.38 0.68
5 INDOCO REMEDIES LIMITED A K Services & Agency Private Limited (Formerly known as A. K. Services) Mrs. Aditi Panandikar Managing Director of the Company is the Director of A K Services & Agency Private Limited Any other transaction Rent Received 2.40 NA 1.20 0.00 0.00
6 INDOCO REMEDIES LIMITED Xtend Industrial Designers and Engineers Pvt. Ltd. Wholly Owned Subsidiary Purchase of goods or services 750.00 NA 19.77 10.18 11.46 Textual Information(3)
7 INDOCO REMEDIES LIMITED Xtend Industrial Designers and Engineers Pvt. Ltd. Wholly Owned Subsidiary Any other transaction Reimbursable Expenses towards ESOP Compensation Cost NA (4.35) 0.81 (3.54)
8 INDOCO REMEDIES LIMITED Florida Pharmaceutical Products, LLC Step Down Subsidiary Any other transaction Providing of corporate guarantee in favour of bank in connection with loan taken by Florida Pharmaceutical Products, LLC 7,000.00 NA 0.00 1,700.00 1,700.00
9 INDOCO REMEDIES LIMITED Florida Pharmaceutical Products, LLC Step Down Subsidiary Sale of goods or services 50.00 NA 3.94 13.98 17.92 Textual Information(4)
10 INDOCO REMEDIES LIMITED Florida Pharmaceutical Products, LLC Step Down Subsidiary Sale of goods or services 7,500.00 NA 4,724.42 5,179.76 9,276.24 Textual Information(5)
11 INDOCO REMEDIES LIMITED FPP Holding Company, LLC Subsidiary Loan 7,000.00 NA 299.50 4,439.25 4,738.75 Textual Information(6)
12 INDOCO REMEDIES LIMITED FPP Holding Company, LLC Subsidiary Any other transaction Interest receivable on ICD Loan provided NA 135.07 610.43 745.51
13 INDOCO REMEDIES LIMITED Suresh Govind Kare (Chairman & Non Executive Director) & Promoter Any other transaction Payment of Sitting Fees NA 0.80 0.00 0.00
14 INDOCO REMEDIES LIMITED Aditi Panandikar Key Management Personnel (MD) & Promoter Remuneration NA 345.48 0.00 0.00
15 INDOCO REMEDIES LIMITED Sundeep V Bambolkar Key Management Personnel (Jt. MD) Remuneration NA 307.65 0.00 0.00
16 INDOCO REMEDIES LIMITED Ramanathan Hariharan Key Management Personnel (CS) Remuneration NA 33.62 0.00 0.00
17 INDOCO REMEDIES LIMITED Pramod Ghorpade Key Management Personnel (CFO) Remuneration NA 94.83 0.00 0.00
18 INDOCO REMEDIES LIMITED Madhura Suresh Kare Promoter Remuneration The Audit Committee has approved maximum limit of Rs. 1 crore per annum for remuneration payable to Ms. Madhura Suresh Kare 29.37 0.00 0.00
19 INDOCO REMEDIES LIMITED Satish Shenoy Independent Director Any other transaction Payment of Sitting Fees NA 2.80 0.00 0.00
20 INDOCO REMEDIES LIMITED Ajay Mulgaokar Independent Director Any other transaction Payment of Sitting Fees NA 3.20 0.00 0.00
21 INDOCO REMEDIES LIMITED Vasudha Kamat Independent Director Any other transaction Payment of Sitting Fees NA 2.80 0.00 0.00
22 INDOCO REMEDIES LIMITED Abhijit Gore Independent Director Any other transaction Payment of Sitting Fees NA 3.20 0.00 0.00
23 INDOCO REMEDIES LIMITED Anand Nadkarni Non Executive and Non Independent Director Any other transaction Payment of Sitting Fees NA 1.80 0.00 0.00
24 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Loan 10,000.00 NA (9,270.00) 9,270.00 0.00
25 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Loan 20,000.00 NA 10,650.00 0.00 0.00
26 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Interest received NA 445.80 1,203.24 0.00
27 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Any other transaction Providing of Corporate Guarantee in favour of bank in connection with loan taken by Warren Remedies Private Limited 30,000.00 NA 2,500.00 23,950.00 26,450.00
28 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Any other transaction Commission on Corporate Guarantee Receivable NA 236.44 638.62 100.23
29 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Any other transaction Interest on corporate guarantee receivable NA 40.35 70.37 20.11
30 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Sale of goods or services 100.00 NA 68.23 96.83 87.03 Textual Information(7)
31 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Purchase of goods or services 4,500.00 NA 633.38 315.15 254.60 Textual Information(8)
32 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Sale of fixed assets 1,500.00 NA 1.57 240.16 1.85 Textual Information(9)
33 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Purchase of fixed assets 1,000.00 NA 0.42 0.00 0.50
34 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Sale of goods or services 500.00 NA 64.25 65.70 69.39 Textual Information(10)
35 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Purchase of goods or services 800.00 NA 29.19 6.17 20.38 Textual Information(11)
36 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Any other transaction Licensing of Brand by Indoco 186.00 NA 186.00 2,634.70 2,547.62
37 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Any other transaction Reimbursable Expenses towards ESOP Compensation Cost NA 5.07 6.24 11.31
38 Xtend Industrial Designers and Engineers Pvt. Ltd. Warren Remedies Private Limited Mrs. Aditi Panandikar & Mr. Sundeep V Bambolkar, Directors of Xtend Industrial Designers and Engineers Pvt. Ltd. are Directors of Warren Remedies Pvt. Ltd. Loan NA 150.00 400.00 550.00
39 Xtend Industrial Designers and Engineers Pvt. Ltd. Warren Remedies Private Limited Mrs. Aditi Panandikar & Mr. Sundeep V Bambolkar, Directors of Xtend Industrial Designers and Engineers Pvt. Ltd. are Directors of Warren Remedies Pvt. Ltd. Interest received NA 21.11 16.71 37.82
40 Warren Remedies Private Limited Suresh Govind Kare Director Loan 1,500.00 NA 1,500.00 0.00 1,500.00
41 Warren Remedies Private Limited Suresh Govind Kare Director Interest received NA 25.67 0.00 0.00
42 Warren Remedies Private Limited Aditi Panandikar Director Loan NA 950.00 0.00 950.00
43 Warren Remedies Private Limited Aditi Panandikar Director Interest received NA 20.40 0.00 0.00
44 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Any other transaction Gratuity obligation of employees transfered from Indoco Remedies Ltd. to Warren Remedies Pvt. Ltd. NA 0.00 68.41 0.00
45 INDOCO REMEDIES LIMITED Warren Remedies Private Limited Wholly Owned Subsidiary Any other transaction Interest overdue on brand licensing by Indoco NA 147.02 233.47 342.44
46 INDOCO REMEDIES LIMITED Florida Pharmaceutical Products, LLC Step Down Subsidiary Any other transaction Commission receivable on Corporate Guarantee provided NA 41.59 0.00 41.59
47 Warren Remedies Private Limited Ulhas Anant Joshi Director Any other transaction Consultancy Fees paid NA 9.80 0.00 0.00
Total value of transaction during the reporting period 14,538.44



Text Block

Textual Information(1) The details mentioned in this row is pertaining to Purchase of Services
Textual Information(2) The details mentioned in this row is pertaining to Purchase of Services
Textual Information(3) The details mentioned in this row is pertaining to Purchase of Services
Textual Information(4) The details mentioned in this row is pertaining to Sale of Services
Textual Information(5) The details mentioned in this row is pertaining to Sale of Products
Textual Information(6) The details mentioned in this row is pertaining to revaluation of existing ICD loan given to FPP Holding Company, LLC
Textual Information(7) This details mentioned in this row is pertaining to Sale of Products
Textual Information(8) The details mentioned in this row is pertaining to Purchase of Products including Finished Goods, RM, PM reimbursement Loan License, raw material, packing material, tools
Textual Information(9) This details mentioned in this row is pertaining to Sale of Assets
Textual Information(10) The details mentioned in this row is pertaining to Sale of Services
Textual Information(11) The details mentioned in this row is pertaining to Purchase of Services